Supernus Pharmaceuticals, a specialty pharmaceutical company focused on developing and commercializing products for the treatment of CNS diseases, has received a $2 million milestone payment under United Therapeutics Corporation's license agreement with the company.
This payment was due upon the launch of Orenitram (treprostinil) extended-release tablets for the treatment of pulmonary arterial hypertension, in the United States. Orenitram utilises a Supernus patented technology platform. In addition to the launch milestone, Supernus will receive royalties on net sales of Orenitram, and may become entitled to additional milestone payments.
"We are pleased to have played a role in helping to bring Orenitram to patients and their physicians as an important new therapy option," said Jack A. Khattar, president and chief executive office, of Supernus. "Over the life of the product, we expect to receive significant recurring royalty revenue from United Therapeutics' commercialisation of Orenitram."